financetom
Business
financetom
/
Business
/
Gilat Satellite Networks Files $150 Million Mixed Shelf
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Gilat Satellite Networks Files $150 Million Mixed Shelf
Aug 28, 2025 1:04 PM

03:53 PM EDT, 08/28/2025 (MT Newswires) -- Gilat Satellite Networks ( GILT ) filed a registration statement Thursday for the potential sale of up to $150 million of securities from time to time in one or more offerings.

The filing covers ordinary shares, warrants to purchase shares or debt securities, debt securities, subscription rights, and units.

Net proceeds will be used for general corporate purposes.

Shares of Gilat Satellite Networks ( GILT ) were down 1.8% in recent trading.

Price: 9.64, Change: -0.18, Percent Change: -1.83

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sector Update: Consumer Stocks Rise Pre-Bell Tuesday
Sector Update: Consumer Stocks Rise Pre-Bell Tuesday
Dec 31, 2024
08:51 AM EST, 12/31/2024 (MT Newswires) -- Consumer stocks were rising in Tuesday's pre-bell hours, with The Consumer Staples Select Sector SPDR Fund ( XLP ) up 0.3% and The Consumer Discretionary Select Sector SPDR Fund ( XLY ) was 0.5% higher. Vera Bradley ( VRA ) shares were up over 2% after the company's largest shareholder, Fund 1 Investments,...
Merck wins UK approval for lung disease drug acquired in $11 bln deal
Merck wins UK approval for lung disease drug acquired in $11 bln deal
Dec 31, 2024
Dec 31 (Reuters) - UK's Medicines and Healthcare products Regulatory Agency said on Tuesday it had approved Merck's ( MRK ) therapy to treat a rare lung condition, marking another win for the drugmaker's potential blockbuster. The therapy, sotatercept, received U.S. approval in March 2024 and is sold under the brand name Winrevair. It is also approved in European Union...
Sangamo's Cash on Balance Sheet Seen as 'Overhang' as Pfizer Pulls Out of Hemophilia A Therapy Study, Truist Says
Sangamo's Cash on Balance Sheet Seen as 'Overhang' as Pfizer Pulls Out of Hemophilia A Therapy Study, Truist Says
Dec 31, 2024
08:41 AM EST, 12/31/2024 (MT Newswires) -- Sangamo Therapeutics' ( SGMO ) cash on its balance sheet remains an overhang following Pfizer's ( PFE ) decision to terminate a hemophilia A gene therapy collaboration with the company, Truist Securities said in a Monday note. The partnership and license agreement between the two companies are anticipated to close in Q1 next...
Kazia Therapeutics Shares Drop After FDA Derails Fast Track of Potential Brain Cancer Drug
Kazia Therapeutics Shares Drop After FDA Derails Fast Track of Potential Brain Cancer Drug
Dec 31, 2024
08:44 AM EST, 12/31/2024 (MT Newswires) -- Kazia Therapeutics ( KZIA ) shares fell more than 6% in pre-market trading Tuesday after the company said it was considering options for its drug candidate paxalisib after the US Food and Drug Administration discouraged an accelerated approval process for the potential glioblastoma treatment. The company said a July study of the drug...
Copyright 2023-2026 - www.financetom.com All Rights Reserved